Clinical Trial Update: ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating clevudine monotherapy, tenofovir monotherapy, and their combination in HBeAg-negative chronic hepatitis B was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Clevudine (clevudine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Conditions: HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection | Phase 3 | Status: TERMINATED